- Subjects must have documented rheumatoid arthritis with a duration of at least 3
months as determined by the investigator using standardly accepted criteria, must have
been receiving methotrexate for at least 3 months to treat their rheumatoid arthritis,
and must be free of any signs or symptoms of infection.
- Subjects cannot enter the study if they have recently received treatment with certain
medications which might interfere with study medications;
- subjects cannot enter if they have abnormalities in certain blood tests, history of
cancer, recent bone fracture or other significant conditions.